Therefore, the aim of this study was to search for a better read-out of activated proteins of the PI3K and MAPK pathways in ER-positive (ER+)/HER2-negative (HER2–) breast cancer patients, predictive for endocrine resistance or associated with prognosis. Here, ERBB2 is linked to breast carcinoma.